Funding for this research was provided by:
Kuopion Seudun Hengityssäätiö
Hengityssairauksien Tutkimussäätiö
Article History
Received: 13 May 2020
Accepted: 11 August 2020
First Online: 20 August 2020
Ethics approval and consent to participate
: The study was approved by the Ethics Committee of Kuopio University Hospital (289/2015). Permission to conduct the study was obtained from officials of the towns. The invitation mail requesting participation in the study included detailed information about the study. The decision of the subject to reply was considered as an informed consent.
: Not applicable.
: HK reports grants from Kuopion Seudun Hengityssäätiö Foundation and from Hengityssairauksien Tutkimussäätiö, during the conduct of the study; personal fees from Mundipharma Ltd., Orion Pharma Ltd., Oy, Eli Lilly Finland Ltd., Boehringer Ingelheim Finland Ltd., MSD Finland Ltd., as payments for giving scientific lectures in gatherings organized by medical companies, personal fees from Takeda Leiras Ltd., Boehringer Ingelheim Ltd., Mundipharma Ltd., and AstraZeneca Ltd., to visit international scientific meetings, and owning shares of Orion Pharma Ltd. worth 30 000 euros.TS reports owning shares of Orion Pharma Ltd. and Novo Nordisk worth 6000 euros.AL reports grants from Kuopion Seudun Hengityssäätiö Foundation, grants from Hengityssairauksien Tutkimussäätiö, during the conduct of the study; personal fees from Orion, Boehringer-Ingelheim, Roche to visit international scientific meetings.